PET Platform

Leveraging decades of experience in developing, improving, and advancing proteins used in human therapeutics.

The Pelican Expression Technology™ platform is uniquein its ability to express complex proteins, such as antibody derivatives, recombinant therapeutic enzymes, vaccine antigens, and other engineered modalities. These complex modalities have the potential for greater specificity, improved side effect profiles and ultimately successful therapeutic outcomes making them the focus of current biopharmaceutical development.

Pelican Expression Technology™ Platform Overview


Our team has established extensive CMC experience and knowledge with Pelican Expression Technology™ through the development of our internal and partnered product portfolio, from preclinical to commercial stage in global markets. Our comprehensive suite of capabilities enables us to de-risk critical manufacturing and regulatory milestones for our partners.

Prior Successes

The Pelican Expression Technology™  platform has demonstrated its versatility through the successful production of a broad range of natural and engineered proteins. We are leveraging that success to create value for our partners.

Intellectual Property

Ligand maintains a broad and comprehensive platform and product intellectual property portfolio with 28 U.S. issued patents as of June 2021 and additional in various stages of prosecution.